To Build Facility for mRNA Bulk Drug Substance by 1H22
Samsung Biologics' CEO John Rim said on June 15 that the company will build a facility to produce mRNA bulk drug substance for Moderna’s mRNA COVID-19 vaccine by the first half of 2022.
"We will be adding a dedicated production suite for mRNA bulk drug substance to our existing facility by the first half of 2022, which will enable us to rapidly manufacture and supply future vaccines and treatments against multiple targets." Rim said in his opening remarks at BIO Digital 2021, which is held online June 10-11 & 14-18.
In his speech, Rim highlighted the industry’s continuing efforts and contribution in the battle against COVID-19 and also shared the company’s vision and long-term plans to better serve existing and potential clients.
“As most recently announced, we are fully committed to leveraging our experience in manufacturing technologies to support the aseptic fill and finish of Moderna’s mRNA-1273 vaccine with quality, speed, and efficiency to aid in the fight against this global crisis,” Rim said.
Other Samsung Biologics' officials are also participating in Bio Digital 2021. Joon Chang, senior director of Global Sales and Operations Center will be presenting during a fireside chat on June 16 on the emerging trends of CDMO industry and its partnership highlighting the unique values that Samsung Biologics delivers to clients.
Also this week, Sam MacHour, senior vice president & chief quality officer, joined Dan Stanton of BioProcess International in an on demand interview, where he discussed how both Samsung Biologics and the CDMO sector have rapidly responded to biopharma's COVID-19 challenges, and talked about how Samsung Biologics has emerged as one of the largest CDMOs in just a decade, as well as its future plans for the CDMO space and beyond.